4-Feb-2026
Globe Newswire (Wed, 14-Jan 8:00 AM ET)
Globe Newswire (Mon, 12-Jan 7:30 AM ET)
Globe Newswire (Thu, 8-Jan 4:30 PM ET)
Globe Newswire (Thu, 8-Jan 8:00 AM ET)
Globe Newswire (Wed, 7-Jan 7:59 AM ET)
Globe Newswire (Fri, 12-Dec 8:30 AM ET)
Globe Newswire (Tue, 18-Nov 8:00 AM ET)
Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors
Globe Newswire (Wed, 12-Nov 4:01 PM ET)
Market Chameleon (Thu, 30-Oct 6:32 AM ET)
EBS Raises Guidance as Margins Improve and Contract Wins Strengthen Outlook
Market Chameleon (Thu, 30-Oct 4:35 AM ET)
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Emergent Biosolutions trades on the NYSE stock market under the symbol EBS.
As of February 4, 2026, EBS stock price declined to $11.41 with 714,432 million shares trading.
EBS has a beta of 2.22, meaning it tends to be more sensitive to market movements. EBS has a correlation of 0.20 to the broad based SPY ETF.
EBS has a market cap of $599.25 million. This is considered a Small Cap stock.
Last quarter Emergent Biosolutions reported $231 million in Revenue and $1.06 earnings per share. This beat revenue expectation by $33 million and exceeded earnings estimates by $1.09.
In the last 3 years, EBS traded as high as $16.66 and as low as $1.42.
The top ETF exchange traded funds that EBS belongs to (by Net Assets): AVUV, VTI, XBI, IWM, FNDA.
EBS has underperformed the market in the last year with a price return of +6.7% while the SPY ETF gained +15.2%. However, in the short term, EBS had mixed performance relative to the market. It has outperformed in the last 3 months, returning +13.1% vs +1.9% return in SPY. But in the last 2 weeks, EBS shares have been beat by the market, returning -0.8% compared to an SPY return of +0.1%.
EBS support price is $11.04 and resistance is $12.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EBS shares will trade within this expected range on the day.